In this study, we investigated the efficacy and molecular mechanisms for the strategy to overcome the extrinsic resistance to FLT3 inhibitors in FLT3-ITD-AML by disrupting the CXCL12/CXCR4 axis with a novel CXCR4 inhibitor, LY2510924. Here, FLT3 is linked to acute myeloid leukemia.